A statement from the chief executive of Eli Lilly, John Lechleiter, made it clear that Eli Lilly and Co had not plans to expand on their diabetes drug partnership with Amylin pharmaceuticals by buying the company. Lechleiter made it clear in a Reuters interview that the relationship is working fine as it is.
Together, the two diabetes companies market the widely used diabetes drug Byetta . By the middle of this year the companies are expected to file for a weekly formulation of the injectable diabetes medication .
Rumours had been circulating that the larger pharmaceutical company would purchase the biotech firm. The alliance between the two companies is one of many around the world, where pharmaceutical companies with capital and distribution/sales networks ally with smaller technological companies.
Diabetes companies no plans to buy
Tue, 28 Apr 2009
Recommended links
Diabetes newsletterDiabetes based financial services
Diabetes forum
Diabetes myLifestyle
Diabetes Donate
Diabetes television study
Diabetes epidemic in Scotland
Diabetics can survive heart transplant
Transplants could hold diabetes risk
Diabetes slows recovery from heart transplant
Plant chemical may fight diabetes
Diabetes screening plan causing concern in Ireland
Diabetics implanted with microchips
Diabetes test burden could be ended by eye implant
Plantain root could have diabetes use
Cell transplant breakthrough for diabetes
Diabetes drug grown in tobacco plants
Transplant procedure could aid diabetics
National diabetes treatment plan in New Zealand
Pioneering islet cell transplants again offer diabetes hope
Diabetes cell transplant approved in New Zealand
No diabetes plan for Care Trusts
Diabetes disaster plan
Environmental concern over NZ diabetes pig call transplants
New hope for diabetes patients from cell transplant
Lilly plans for Japan diabetes market
Join us